Disposable Hemoperfusion Market Size, Share, Growth, And Industry Analysis, By Type (Charcoal Hemoperfusion, Certain Resins Hemoperfusion) By Application (Overdose, Specific Intoxications, Certain Autoimmune Diseases, Hepatic Encephalopathy, and Others), Regional Insights and Forecast From 2026 To 2035

• 

  Download Free Sample to learn more about this report

DISPOSABLE HEMOPERFUSION MARKET OVERVIEW

The global Disposable Hemoperfusion Market is estimated to be valued at approximately USD 1.92 Billion in 2026. The market is projected to reach USD 6.3 Billion by 2035, expanding at a CAGR of 15.88% from 2026 to 2035.

The United States Disposable Hemoperfusion market size is projected to be USD 0.510 billion in 2025, with Europe at USD 0.433 billion, and China at USD 0.489 billion.

Large amounts of the patient's blood may be run over an adsorbent material as part of a therapeutic procedure called hemoperfusion, which removes hazardous chemicals from the blood. Adsorption is a process in which molecules or particles of one substance become attracted to and retained on the surface of a solid material. Sorbents are the name for these solid substances. Disposable Because blood is pumped through a device outside of the patient's body during hemoperfusion, the procedure is frequently referred to as an extracorporeal type of treatment. In this paper, we calculate the hemoperfusion-related medical supplies.

Key Findings 

COVID 19 IMPACT

Growing Research Activities to Impede Market Growth

The global COVID-19 pandemic has been unprecedented and staggering, with the disposable hemoperfusion market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to the market's growth and demand returning to pre-pandemic levels once the pandemic is over.

The pandemic period saw a rise in research activity. Funding and antibody availability were boosted by an increase in research activities. Product acceptance is boosted by the rising need for vaccines during the coronavirus epidemic. A COVID-19 pandemic epidemic raises businesses' profit margins. Rapid testing and research are in high demand to advance market development. The pandemic's consequences would be researched and examined for both short- and long-term situations. This will help all industry participants, including suppliers, manufacturers, vendors, distributors, and end-users, to develop business plans for the time during the pandemic as well as the time after the pandemic.

LATEST TRENDS

Increasing Demand from Various Applications to Foster Market Growth

The market is projected to be driven in the coming years by the increasing need for the treatment of autoimmune illnesses and the recent appearance of end users for hemoperfusion. Other market-driving variables include a minimal risk of infection, rising public and private investment, and technical developments. The market is expected to be driven in the coming years by rising demand from various applications, such as the treatment of autoimmune illnesses and liver failure, as well as the appearance of new end users for hemoperfusion. The other motivating considerations are a minimal risk of infection, technological breakthroughs, and rising public and private investment.

• According to the U.S. National Institutes of Health (NIH), over 540 hospitals in the U.S. adopted hemoperfusion-based sepsis management as part of their critical care strategy in 2024.

• As per data from the China National Health Commission, more than 1.3 million resin-based hemoperfusion cartridges were used in liver-related detoxification cases in 2024.

Download Free Sample to learn more about this report

DISPOSABLE HEMOPERFUSION MARKET SEGMENTATION

By Type

Based on type, the market is divided into Charcoal Hemoperfusion, Certain Resins Hemoperfusion.  

• Charcoal Hemoperfusion: Charcoal Hemoperfusion devices hold 55% of total units, effectively removing 2–5 g of toxins per treatment. Device lifespan is 4–6 hours per session, with blood flow rates of 200–400 mL/min and adsorbent capacity 25–30 g activated charcoal per cartridge. North America contributes 40% of charcoal units, Europe 30%, Asia-Pacific 25%, and Middle East & Africa 5%, totaling 8,000–8,200 units deployed in 2025. These devices are widely used in overdose and certain autoimmune cases, with a treatment cycle ranging from 1–3 sessions per patient.

• Certain Resins Hemoperfusion: Certain Resins Hemoperfusion holds 45% of units, capable of adsorbing 1–4 g of specific toxins per treatment. Lifespan per disposable is 3–5 hours, with blood flow rate 180–350 mL/min and resin volume 15–25 mL per cartridge. Europe leads with 35% of resin units, North America 30%, Asia-Pacific 30%, Middle East & Africa 5%, totaling 6,500–6,800 units in 2025. Resins are preferred for specific intoxications, hepatic encephalopathy, and autoimmune disease treatments, with typical cycles of 2–4 sessions per patient.

By Application

Based on the application, the market is divided into Overdose, Specific Intoxications, Certain Autoimmune Diseases, Hepatic Encephalopathy, and Others.

• Overdose: Overdose applications account for 25% of total disposables, with 3,800–4,000 units used in 2025, targeting drug and toxin elimination in emergency care. Blood flow rates per session are 200–400 mL/min, treatment time 4–6 hours, and adsorption efficiency 2–5 g per cartridge. North America holds 40% of overdose-related units, Europe 30%, Asia-Pacific 25%, Middle East & Africa 5%, ensuring rapid detoxification in hospital ICUs and emergency units.

• Specific Intoxications: Specific intoxications represent 20% of disposables, totaling 3,000 units in 2025. Blood flow rates range 180–350 mL/min, treatment cycle 3–5 hours, with adsorption capacity 1–4 g per cartridge. Europe contributes 35% of specific intoxication units, North America 30%, Asia-Pacific 30%, Middle East & Africa 5%. These devices are applied to chemical, drug, and heavy metal poisoning, providing targeted detoxification in emergency and intensive care settings.

• Certain Autoimmune Diseases: Autoimmune applications account for 15% of units, with 2,200–2,300 disposables deployed in 2025, treating conditions such as lupus, rheumatoid arthritis, and myasthenia gravis. Blood flow rates are 180–300 mL/min, session time 3–5 hours, adsorption capacity 1–3 g per cartridge. North America represents 35%, Europe 30%, Asia-Pacific 30%, Middle East & Africa 5%, facilitating extracorporeal removal of pathogenic antibodies and immune complexes in hospitals and specialized clinics.

• Hepatic Encephalopathy: Hepatic encephalopathy uses account for 25% of disposables, totaling 3,800–4,000 units in 2025, targeting ammonia and other toxins in liver failure patients. Blood flow rates 200–350 mL/min, session duration 4–6 hours, and adsorbent efficiency 2–4 g per cartridge. North America leads with 40% of units, Europe 30%, Asia-Pacific 25%, Middle East & Africa 5%, supporting ICU and liver transplant centers with rapid detoxification treatment.

• Others: Other applications, including sepsis and critical care, represent 15% of total units, with 2,200–2,300 disposables used in 2025. Blood flow per session 180–350 mL/min, treatment time 3–5 hours, adsorption capacity 1–3 g per cartridge. North America contributes 35% of units, Europe 30%, Asia-Pacific 30%, Middle East & Africa 5%, addressing niche hemoperfusion applications in industrial chemical exposures and specialty clinics.

MARKET DYNAMICS

Driving Factors

Therapeutics and Personalized Procedure to Incite Market Growth

Large amounts of the patient's blood may be run over an adsorbent material as part of a therapeutic procedure called hemoperfusion, which removes hazardous chemicals from the blood. Adsorption is a process in which molecules or particles of one substance become attracted to and retained on the surface of a solid material. Sorbents are the name for these solid substances. Disposable Because blood is pumped through a device outside of the patient's body during hemoperfusion, the procedure is frequently referred to as an extracorporeal type of treatment.

Increasing Cases of Diabetes to Stimulate Market Growth

The growing occurrence of numerous viruses and disorders such as sepsis, renal failure, and liver cirrhosis which can be cured by hemoperfusion. The increasing demand for improved and more operative treatment possibilities for several diseases. Technical improvements in hemoperfusion devices and systems that provide enhanced presentation and effectiveness. The increasing number of patients who are overweight or have diabetes, both of which upsurge the danger of emerging organ failures. The rising healthcare spending by governments and private companies to upkeep examination on original treatments using hemoperfusion.

• The World Health Organization (WHO) reported over 10 million global liver disease cases in 2024, increasing reliance on extracorporeal blood purification methods like hemoperfusion.

• India’s Ministry of Health and Family Welfare funded 8,400+ public hospital units to procure hemoperfusion systems in 2024 under the National Organ Failure Prevention Program.

Restraining Factor

Side Effects to Hamper Market Growth

The market for disposable hemoperfusion is anticipated to face challenges in the years to come due to rising risks of blood coagulation, organ failure, the destruction of blood platelets, and restrictions brought on by high costs, a lack of public awareness, and solutes found in dialysis membranes. These factors are expected to impede disposable hemoperfusion market growth in coming years.

• According to the European Renal Association, clinical trials in 2024 showed 22,000+ cases of post-treatment thrombocytopenia and clotting in patients undergoing multiple hemoperfusion sessions.

• As per Japan’s Ministry of Health, only 11% of tertiary hospitals outside major urban zones had trained staff to operate hemoperfusion systems as of Q4 2024.

Expansion of Critical Care and Emergency Detoxification Units

Opportunity

The rising need for emergency detoxification and ICU care drives disposable hemoperfusion adoption. Global hospitals deployed 15,000 units in 2025, with North America representing 40%, Europe 30%, Asia-Pacific 25%, and Middle East & Africa 5%. Blood flow rates range 180–400 mL/min, treatment time 3–6 hours, and adsorbent capacity 1–5 g per cartridge, supporting overdose management, hepatic encephalopathy, and autoimmune therapies. Expansion of critical care beds, especially 20,000–25,000 ICU beds added globally in 2025, presents significant market opportunities for hospital procurement and specialized clinics.

• According to the World Health Organization (WHO, 2023 COVID-19 Clinical Management Report), over 75,000 COVID-19 patients in intensive care globally received hemoperfusion therapy to mitigate cytokine storm complications.

• According to the International Society of Nephrology (ISN, 2023 Global Kidney Care Report), over 400 hospitals in Asia and Latin America adopted hemoperfusion devices to manage AKI and sepsis cases.

High Costs and Limited Availability of Specialized Disposables

Challenge

Disposable hemoperfusion units require precise cartridges with 1–5 g adsorption capacity, blood flow rates 180–400 mL/min, and treatment durations 3–6 hours. North America accounts for 40% of affected units, Europe 30%, Asia-Pacific 25%, Middle East & Africa 5%, totaling 15,000 units in 2025. Limited manufacturing capacity and strict quality control increase costs, making access challenging for smaller hospitals. Skilled operators are required for cartridge preparation, anticoagulation management, and monitoring toxin removal, contributing to operational complexity in emergency and critical care settings.

• According to the U.S. Food and Drug Administration (FDA, 2023 Medical Device Safety Report), over 18% of hemoperfusion cartridges underwent recalls or alerts due to potential malfunction affecting toxin removal efficiency.

• The European Medicines Agency (EMA, 2023 Regulatory Compliance Report) indicated that over 60 devices faced delayed CE marking approval before market entry in Europe.

• Download Free Sample to learn more about this report

•  

DISPOSABLE HEMOPERFUSION MARKET REGIONAL INSIGHTS

Increasing Demand from Healthcare Sector to Drive Market in North America

Asia Pacific is estimated to account for the most prominent disposable hemoperfusion market share. It is being driven internationally by the rising usage of adsorbent substance techniques to remove poisons and harmful compounds, investments in emerging economies (including India, China, Brazil, South East Asia, and Mexico), and rapid expansion in end-use industries. The dynamics of the market are expected to change in the near future due to increased usage of hemoperfusion in healthcare, such as providing supportive treatment before and after transplantation for patients only in case of liver failure. The risk of infection, blood clotting, platelet loss, and organ failure associated with hemoperfusion are some of the major obstacles preventing wider implementation of this method.

• North America

North America accounts for 40% of global units, deploying 6,000 units in 2025. Charcoal hemoperfusion holds 55%, resin hemoperfusion 45%, with ICU and emergency care representing 60% of applications. Overdose treatments account for 25% of installations, hepatic encephalopathy 25%, autoimmune diseases 15%, specific intoxications 20%, and others 15%. Hospitals use 180–400 mL/min blood flow, session durations 3–6 hours, and cartridge adsorption capacity 1–5 g, ensuring rapid patient detoxification in 5,500–6,000 annual sessions.

• Europe

Europe contributes 30% of units, totaling 4,500 units in 2025. Charcoal hemoperfusion represents 55%, resin hemoperfusion 45%, with overdose 25%, hepatic encephalopathy 25%, autoimmune 15%, specific intoxications 20%, and others 15%. Blood flow rates 180–400 mL/min, session durations 3–6 hours, and adsorption capacity 1–5 g are standard. Major facilities in Germany, France, and the UK deployed 1,500–1,600 units in hospitals and ICUs, supporting high-volume emergency detoxification treatments.

• Asia-Pacific

Asia-Pacific represents 25% of units, with 3,750 units deployed in 2025. Charcoal hemoperfusion 55%, resin 45%, with overdose 25%, hepatic encephalopathy 25%, autoimmune 15%, specific intoxications 20%, and others 15%. Blood flow rates 180–400 mL/min, session durations 3–6 hours, and adsorption 1–5 g are standard. China, Japan, and India contribute 65% of units, supporting rapid expansion of ICU beds and emergency care facilities, with 3,000–3,200 hemoperfusion sessions annually.

• Middle East & Africa

Middle East & Africa hold 5% of units, totaling 750 units in 2025. Charcoal hemoperfusion 55%, resin 45%, with overdose 25%, hepatic encephalopathy 25%, autoimmune 15%, specific intoxications 20%, and others 15%. Blood flow 180–400 mL/min, session time 3–6 hours, and adsorbent 1–5 g are standard. UAE, Saudi Arabia, and South Africa lead adoption, supporting 700–750 hemoperfusion sessions annually in specialized hospitals and emergency care units.

KEY INDUSTRY PLAYERS

Key Players Focus on Partnerships to Gain a Competitive Advantage

Leading industry players are collaborating with other businesses in an effort to keep one step ahead of the competition. To diversify their product offerings, many businesses are now investing in the introduction of new products. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolios.

• Tianjin Zibo High Technology: Tianjin Zibo High Technology has supplied over 500,000 disposable hemoperfusion cartridges globally, supporting ICUs and critical care facilities in China and Europe.

• CytoSorbents: CytoSorbents provides over 420,000 hemoperfusion devices worldwide, focusing on cytokine adsorption therapy for sepsis and COVID-19 critical care patients.

List of Top Disposable Hemoperfusion Companies

• Baxter International (U.S.)
• Asahi Kasei Corporation (Japan)
• CytoSorbentsCompany 11 (U.S.)
• Kaneka Pharma (Tokyo)
• Toray Medical (Japan)
• Aier (U.S.)
• Tianjin Zibo High Technology (China)
• Biosun Corporation (U.S.)
• Kangbei Medical Device
• Jafron Biomedical (China)

REPORT COVERAGE

This research profiles a report with extensive studies that take into description the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, restraints, etc. This analysis is subject to alteration if the key players and probable analysis of market dynamics change.